Needham Reiterates Buy on Taysha Gene Therapies, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $5 price target.
September 20, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a 'Buy' rating on Taysha Gene Therapies, maintaining a $5 price target.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Taysha Gene Therapies. The maintained price target of $5 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100